附近上门

In medical-related funding news, three companies focused on developing treatments, therapies and medicines for cancer patients have announced supergiant rounds.

Subscribe to the 附近上门 Daily

Across the sea, German unicorn announced it a massive $325 million Series B in what it described as 鈥渙ne of the largest single private rounds for a biotech company in European history.鈥� The eleven-year-old clinical-stage company is developing immunotherapies for the treatment of cancer and other serious diseases. led the round, which also included participation from a slew of . The raise comes just over 18 months after it raised led by at a $2 billion pre-money valuation.

Closer to home, Redwood City-based Revolution Sciences has on a $100 million Series C led by biotech-focused l. The four-year-old startup discovers and develops new medicines for cancer patients, per its , and has raised over its lifetime, according to its 附近上门 profile.

And, as Axios reported this morning, Mountain View-based , which is also focused on developing drugs for cancer patients, has in Series C funding from Redmile Group, , and .

BioNTech says it was founded on the premise 鈥渢hat every cancer patient鈥檚 tumor is unique and therefore each patient鈥檚 treatment should be individualized.鈥� Revolution is working to 鈥渢ranslate frontier oncology targets,鈥� or what it describes as 鈥減roteins that drive the growth of cancers or that control immune responses that can defeat them.鈥� And, IGM Biosciences is focused on 鈥渃reating and developing engineered IgM antibodies for the treatment of cancer patients.鈥�

Sadly, I鈥檓 sure almost all of us have lost a loved one or friend to cancer. It鈥檚 safe to say that I鈥檓 rooting for any company that aims to help cancer patients. Here鈥檚 to hoping that these millions of dollars of funding will help save more lives.

Illustration: